This Biotech with Breakout MS Drug Draws Big Investment
A breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
Check which passive funds beat the market in 2024 retirement planning and what factors contributed to their outperformance.
28,482 articlesA breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
Markets grapple with a hypothetical energy shock after a White House remark suggesting oil could surge to $200 per ba...
A dramatic one-day move put Relay Therapeutics in the spotlight. After encouraging Phase 2 results for zovegalisib an...
Polymarket cuts ties with former Rep. George Santos as federal regulators widen a probe into whether he bet against h...
As oil prices rebound in 2026, investors weigh the three biggest U.S. oil majors. This report outlines buy, sell or h...
After 15 years of bullish calls on banks, a veteran analyst pivots to private equity and other alternatives, downgrad...
An insider move at a biotech stage company can spark questions. This article breaks down the trade, its timing, and w...
Santander sinks 12.6% as unconfirmed trade news swirls around US-Spain tensions, but the bank’s 2025 profits and effi...
Two must-see graphs explain a dramatic stock surge and outline why the rally could keep running. This guide translate...
Apple doubles down on returning capital to shareholders with a $100 billion buyback and a dividend hike, while rivals...
As the AI arms race accelerates, Microsoft leans on Copilot to reverse signals of lost momentum. Early traction and p...
Actor tate donovan sells a Texas Hill Country oasis after a price cut, with the sale closing in late May 2026 and pri...